Second-generation anti-obesity peptide medications achieve average 15% weight loss — far surpassing first-generation drugs — with semaglutide 2.4 mg and tirzepatide also effectively treating concurrent type 2 diabetes.
~15% weight lossSecond-generation anti-obesity peptide drugs achieve about 15% average weight loss with lifestyle modifications, far exceeding first-generation medications
What the researchers found
Second-generation anti-obesity medications achieve ~15% average weight loss with lifestyle modifications. Three approved drugs: setmelanotide (monogenic obesity), semaglutide 2.4 mg, and tirzepatide. Semaglutide and tirzepatide are particularly effective when treating concurrent obesity and T2D.
Why it matters
Obesity affects over 40% of US adults and first-generation medications offered only modest weight loss. The 15% average weight reduction achieved by these peptide drugs is clinically meaningful — enough to significantly reduce cardiovascular risk, improve diabetes control, and reduce the need for bariatric surgery.
The numbers in context
Average weight loss of ~15% with lifestyle modifications. Three approved drugs reviewed: setmelanotide, semaglutide 2.4 mg, and tirzepatide.
How the study worked
Narrative review examining clinical trial data and therapeutic implications of the three approved second-generation anti-obesity medications.
Who was studied
Review covering adults with obesity and concurrent type 2 diabetes
What this study cannot tell us
Short review with limited abstract detail. Doesn't discuss cost, access barriers, or long-term safety. Weight regain upon discontinuation not addressed. Setmelanotide applies only to rare monogenic obesity. Real-world effectiveness may differ from clinical trial results.
How to read the evidence
Rated strong: review synthesizing robust clinical trial evidence for all three approved medications, published in a diabetes specialty journal.
When this study was published
Published in 2024. Covers the current approved landscape of peptide-based anti-obesity medications.
The bigger picture
These peptide-based obesity drugs represent a paradigm shift — for the first time, medications can achieve weight loss approaching that of bariatric surgery. This has transformed obesity from a condition with limited medical options to one with multiple effective pharmacological treatments.
Questions still open
- How do the next-generation drugs (survodutide, retatrutide) compare to current options?
- What strategies can maintain weight loss after drug discontinuation?
- How should clinicians choose between semaglutide and tirzepatide for individual patients?
Common questions
What are the best weight loss medications available now?
How much weight can you lose with semaglutide or tirzepatide?
Read the original research
Using Second-Generation Anti-Obesity Medications.
Diabetes spectrum : a publication of the American Diabetes Association, 37(4), 303-312
Citation
Schmitz, Sarah H; Aronne, Louis J. (2024). Using Second-Generation Anti-Obesity Medications.. Diabetes spectrum : a publication of the American Diabetes Association, 37(4), 303-312. https://doi.org/10.2337/dsi24-0002